Skip to content

Ken Mackie

3 papers in the library · 9 citations · publishing 2008-2025

Papers

Sort Most recent Most cited

Muscarinic cannabinoid suppression of excitation, a novel form of coincidence detection.

Pharmacological Research February 1, 2025 Michaela Dvorakova, Ken Mackie, Alex Straiker 2 citations

Δ9-tetrahydrocannabinol (THC), the chief psychoactive ingredient of cannabis, acts in the brain primarily via cannabinoid CB1 receptors. These receptors are implicated in several forms of synaptic plasticity - depolarization-induced suppression of excitation (DSE), metabotropic suppression of excitation (MSE), long term depression (LTD) and activation-dependent desensitization. Cultured...

Hexahydrocannabinol (HHC) and Δ9-tetrahydrocannabinol (Δ9-THC) driven activation of cannabinoid receptor 1 results in biased intracellular signaling

Scientific Reports April 22, 2024 Oleh Durydivka, Petr Palivec, Matej Gazdarica et al. 7 citations

Abstract The Cannabis sativa plant has been used for centuries as a recreational drug and more recently in the treatment of patients with neurological or psychiatric disorders. In many instances, treatment goals include relief from posttraumatic disorders, anxiety, or to support treatment of chronic pain. Ligands acting on cannabinoid receptor 1 (CB1R) are also potential targets for the...

Signaling via CNS cannabinoid receptors.

Molecular and cellular endocrinology April 16, 2008 Ken Mackie

Because of the prominent psychoactive effects of cannabis and its preparations, much research has focused on the actions of cannabinoids, the primary psychoactive components of cannabis, on neuronal function. A convergence of research has identified (1) cannabinoid receptors, (2) endogenous compounds that activate these receptors (endocannabinoids), and (3) drugs that interact with these...